李自成 教授医学博士,暨南大学附属第一医院心内科主任医师、教授、博士生导师。从事心血管病临床诊治工作近40年。主要研究方向为高血压与动脉粥样硬化防治和冠心病经皮冠状动脉介入术(PCI)后再狭窄防治研究,以第一作者发表学术论著(包括SCI论文)120余篇。有独立从事心脏起搏术(包括无导线起搏)、冠心病介入诊治术 [包括血管内超声(IVUS)、光学干涉断层成像技术(OCT)、冠脉内旋磨术、冠脉内药物球囊成形术、冠脉内可吸收支架植入术等]、肾动脉内支架术、先天性心脏病介入封堵术、二尖瓣球囊成形术、肺动脉瓣球囊成形术和经导管主动脉瓣置换术(TAVR)等介入治疗术6000余例的临床经验。 中国远程心电监护专家委员会委员,中国健康管理协会高血压防治与管理专业委员会委员,广东省胸痛中心协会副理事长,广东省健康管理学会副主任委员,广东省医学会心血管病分会常委,广东省医师协会心血管内科医师分会常委,广东省中西医结合学会介入性心脏病分会副主任委员,广东省介入性心脏病学会理事。《临床心血管病杂志》、《实用医学杂志》、《岭南心血管病杂志》等杂志编委,《中国病理生理杂志》、《中国心脏起搏与心电生理杂志》、《暨南大学学报》、《广东医学》等杂志特约审稿人。 参考文献:[1]Nasution SA. The use of ACE inhibitor in cardiovascular disease. Acta medica Indonesiana. 2006;38:60-4.[2]Taddei S and Bortolotto L. Unraveling the pivotal role of bradykinin in ACE inhibitor activity. American Journal of Cardiovascular Drugs. 2016;16:309-321.[3]Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest. 2006;129:169S-173S.[4]Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI and Gallagher PE. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111:2605-2610.[5]Jiang F, Yang J, Zhang Y, Dong M, Wang S, Zhang Q, Liu FF, Zhang K and Zhang C. Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets. Nature Reviews Cardiology. 2014;11:413-426.[6]Patel VB, Takawale A, Ramprasath T, Das SK, Basu R, Grant MB, Hall DA, Kassiri Z and Oudit GY. Antagonism of angiotensin 1–7 prevents the therapeutic effects of recombinant human ACE2. Journal of molecular medicine. 2015;93:1003-1013.[7]Chiu AT, Herblin WF, McCall DE, Ardecky RJ, Carini DJ, Duncia JV, Pease LJ, Wong PC, Wexler RR and Johnson AL. Identification of angiotensin II receptor subtypes. Biochemical and biophysical research communications. 1989;165:196-203.[8]Miura S-i, Karnik SS and Saku K. Angiotensin II type 1 receptor blockers: class effects versus molecular effects. Journal of the Renin-Angiotensin-Aldosterone System. 2011;12:1-7.[9]Mehta PK and Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. American Journal of Physiology-Cell Physiology. 2007;292:C82-C97.[10]Dhande I, Ma W and Hussain T. Angiotensin AT 2 receptor stimulation is anti-inflammatory in lipopolysaccharide-activated THP-1 macrophages via increased interleukin-10 production. Hypertension Research. 2015;38:21-29.[11]Senchenkova EY, Russell J, Esmon CT and Granger DN. Roles of coagulation and fibrinolysis in angiotensin II‐enhanced microvascular thrombosis. Microcirculation. 2014;21:401-407.[12]Pavlov M, Nikolić-Heitzler V, Babić Z, Milošević M, Kordić K, Ćelap I and Degoricija V. Plasminogen activator inhibitor-1 activity and longterm outcome in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: a prospective cohort study. Croatian medical journal. 2018;59:108-117.[13]Numaguchi Y, Ishii M, Kubota R, Morita Y, Yamamoto K, Matsushita T, Okumura K and Murohara T. Ablation of angiotensin IV receptor attenuates hypofibrinolysis via PAI-1 downregulation and reduces occlusive arterial thrombosis. Arteriosclerosis, thrombosis, and vascular biology. 2009;29:2102-2108.[14]Schieffer B, Bünte C, Witte J, Hoeper K, Böger RH, Schwedhelm E and Drexler H. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. Journal of the American College of Cardiology. 2004;44:362-368.[15]Lenglet S, Mach F and Montecucco F. Role of matrix metalloproteinase-8 in atherosclerosis. Mediators of inflammation. 2013;2013.[16]Gough PJ, Gomez IG, Wille PT and Raines EW. Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. The Journal of clinical investigation. 2006;116:59-69.[17]Lods N, Ferrari P, Frey FJ, Kappeler A, Berthier C, Vogt B and Marti H-P. Angiotensin-converting enzyme inhibition but not angiotensin II receptor blockade regulates matrix metalloproteinase activity in patients with glomerulonephritis. Journal of the American Society of Nephrology. 2003;14:2861-2872.[18]Du F, Zhou J, Gong R, Huang X, Pansuria M, Virtue A, Li X, Wang H and Yang X-F. Endothelial progenitor cells in atherosclerosis. Frontiers in bioscience: a journal and virtual library. 2012;17:2327.[19]Simard T, Jung RG, Motazedian P, Di Santo P, Ramirez FD, Russo JJ, Labinaz A, Yousef A, Anantharam B and Pourdjabbar A. Progenitor cells for arterial repair: incremental advancements towards therapeutic reality. Stem cells international. 2017;2017.[20]Ferrari R and Fox K. Insight into the mode of action of ACE inhibition in coronary artery disease. Drugs. 2009;69:265-277.[21]Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet (London, England). 2003;362:782-8.[22]Sleight P. The HOPE Study (Heart Outcomes Prevention Evaluation). Journal of the renin-angiotensin-aldosterone system : JRAAS. 2000;1:18-20.[23]Group I-C. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet (London, England). 1995;345:669-85.[24]Miocardico GIplSdSni. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. . Lancet (London, England). 1994;343:1115-22.[25]Group CC. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet (London, England). 1995;345:686-7.[26]Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P and Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-59.[27]Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G and Sleight P. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet (London, England). 2008;372:1174-83.[28]Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B and Zanchetti A. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet (London, England). 2004;363:2022-31.[29]Turnbull F, Neal B, Pfeffer M, Kostis J, Algert C, Woodward M, Chalmers J, Zanchetti A and MacMahon S. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. Journal of hypertension. 2007;25:951-8.[30]Savarese G, Costanzo P, Cleland JG, Vassallo E, Ruggiero D, Rosano G and Perrone-Filardi P. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. Journal of the American College of Cardiology. 2013;61:131-42.[31]Cheng J, Zhang W, Zhang X, Han F, Li X, He X, Li Q and Chen J. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med. 2014;174:773-85.[32]Hoang V, Alam M, Addison D, Macedo F, Virani S and Birnbaum Y. Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Coronary Artery Disease without Heart Failure in the Modern Statin Era: a Meta-Analysis of Randomized-Controlled Trials. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy. 2016;30:189-98.[33]Shen J, Huang YM, Song XN, Hong XZ, Wang M, Ling W, Zhang XX and Zhao HL. Protection against death and renal failure by renin-angiotensin system blockers in patients with diabetes and kidney disease. Journal of the renin-angiotensin-aldosterone system : JRAAS. 2016;17.[34]Ferrari R and Boersma E. The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review. Expert review of cardiovascular therapy. 2013;11:705-17.[35]中国心血管病预防指南写作组 and 中华心血管病杂志编辑委员会. 中国心血管病预防指南(2017). 中华心血管病杂志. 2018;46:10-25.[36]Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio AL, Crea F, Goudevenos JA and Halvorsen S. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European heart journal. 2018;39:119-177.[37]王斌, 李毅 and 韩雅玲. 稳定性冠心病诊断与治疗指南. 中华心血管病杂志. 2018;46:680r694.[38]Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, De Simone G and Dominiczak A. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European heart journal. 2018;39:3021-3104.[39]Collet J-P, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T and Folliguet T. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European heart journal. 2021;42:1289-1367.ACMKT20211227073 仅供医疗卫生专业人士为了解资讯使用。该等信息不能以任何方式取代专业的医疗指导,也不应被视为诊疗建议。如该等信息被用于了解资讯以外的目的,本平台及作者不承担相关责任。此文仅用于向医疗卫生专业人士提供科学信息,不代表平台立场